Drugs that contain Netupitant; Palonosetron Hydrochloride
1. Drug name - AKYNZEO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6297375 | HELSINN HLTHCARE | 4-phenyl-pyridine derivatives |
Mar, 2023
(5 months from now) | |
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| CN107001275A | HELSINN HLTHCARE | Form Of Nk-1 Antagonist |
Nov, 2019
(2 years ago) | |
| CN1142144C | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| CN1270959A | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| IN215447B | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| IN200000144I4 | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| EP1394150A1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1394150B1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1035115B1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1035115A1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(8 years from now) | |
| US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(8 years from now) | |
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 300MG;EQ 0.5MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.